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Go for Hematopoietic Cell Transplantation Eligibility?
Jason W. Chien,1,2 Keith M. Sullivan3Current guidelines suggest that patients with a pretransplantation diffusion capacity of the lung for carbon
monoxide (DLCO) # 60% are not ideal candidates for hematopoietic cell transplantation (HCT); however,
recent studies suggest this criterion may exclude patients who will benefit from the procedure. We
conducted a study of all adult patients who underwent autologous or allogeneic HCT between 1990 and
2005, and had a DLCO\ 60%, of predicted normal, to examine whether there is a lower limit for the
DLCO threshold in the context of respiratory failure and nonrelapse mortality risk (NRM), and whether
a comprehensive risk scoring system, such as the Pretransplant Assessment of Mortality (PAM) risk score,
can more effectively risk stratify these patients with a very low pretransplantation DLCO. We found that
among patients with a DLCO # 60% the risk of respiratory failure or NRM was not significantly different;
however, the PAM score effectively risk-stratified these patients for NRM risk. Therewas a stepwise relation-
ship between PAM score category andNRM risk; the highest PAM score category was associated with a 4.38-
fold increase in risk (P\.001). These findings suggest that the pretransplantation DLCO should not be con-
sidered the sole eligibility criteria for allogeneic HCT.
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It is well accepted that pretransplantation lung func-
tion assessmentprovides critical information for theman-
agement of patients undergoing hematopoietic cell
transplantation (HCT), and that pulmonary function
tests (PFTs) should be obtained before both autologous
and allogeneic HCT as part of standard practice proto-
cols for evaluating lung function as an eligibility criteria
for transplantation [1-3]. Many studies have examined
the predictive value of pretransplantation PFTs for post-
transplantation outcomes, such as pulmonary complica-
tions and mortality [2-7]. Although these studies were
not definitive, a seminal study of a large cohort by Craw-
ford and Fisher [8] found that patients with a pretrans-
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6/j.bbmt.2008.12.509monoxide (DLCO)\ 60% had a 1.5-fold higher risk
for mortality after transplantation [8]. This observation
was extended in a follow-up study demonstrating that pa-
tients with a pretransplantation DLCO\ 70% of the
predicted normal had a 2.4-fold increased risk for severe
hepatic veno-occlusive disease (VOD) after marrow
transplantation [9]. Based on these findings, current Na-
tionalMarrowDonorProgram (NMDP) transplantation
eligibility guidelines suggest that in the absence of other
comorbid conditions, a DLCO threshold of 60% should
be considered as an eligibility criterion for stemcell trans-
plantation; that is, patients with a DLCO# 60% should
not undergo transplantation [10].
But, the results of several recent studies suggest that
transplantation outcome (e.g., mortality) likely depends
on multiple baseline risk factors and comorbidities,
including, but not limited to, DLCO [11-15]. Based on
several studies, Sorror and coworkers [13-15] concluded
that a comprehensive assessment of 18 pretransplanta-
tion comorbid conditions is informative and predictive
in terms of a patient’s risk for nonrelapse mortality
(NRM) and survival. We have taken a parsimonious ap-
proach, demonstrating that 8 commonly available pre-
transplantation clinical variables can accurately predict
the riskof all-causemortalitywithin thefirst 2 years after
allogeneic HCT [11]. Based on these findings, we urge
the transplantation community to consider not using
any single variable, such as the DLCO, as the sole
criterion for transplantation eligibility.447
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a DLCO threshold should be used as an eligibility
criterion merits reassessment. Consequently, we ana-
lyzed a cohort of patients with a pretransplantation
DLCOof# 60% to determinewhether there is a lower
limit for the DLCO threshold in the context of
posttransplantation outcomes. We also investigated
whether a comprehensive risk scoring system can
more effectively risk-stratify this subgroup of patients
with very low pretransplantation DLCO and identify
those patients who are more likely to benefit from
this potentially dangerous procedure.PATIENTS AND METHODS
Patient Selection
This study was conducted using clinical and labo-
ratory data collected prospectively at the Fred Hutch-
inson Cancer Research Center/Seattle Cancer Care
Alliance (the ‘‘Center’’ hereinafter). All patients who
underwent a first autologous or allogeneic HCT
between January 1, 1990, and December 31, 2005,
had a DLCO # 60% of predicted normal, and were
aged $ 15 years were included in this study.Clinical Variables
The Pretransplant Assessment of Mortality (PAM)
is a comprehensive scoring system that can be used to
accurately estimate a patient’s risk for all-causemortal-
ity within the first 2 years after allogeneic HCT [11].
This scoring system has been validated in multiple
patient cohorts, including patients who also received
a reduced-intensity conditioning (RIC) regimen be-
fore HCT. PAM score components—age at transplan-
tation, disease risk, donor type, conditioning regimen,
and liver, kidney, and lung function—were collected
and scored for all patients as described previously
[11]. To simplify the disease categories for the analysis,
we ranked them as low, intermediate, or high risk ac-
cording to disease type, stage, and our experience
with their outcomes. Donor–recipient matching was
determined according to donor–recipient ABO com-
patibility and HLA-A, -B, and -DR compatibility.
Conditioning regimens were first grouped according
to myeloablative or nonmyeloablative category. Mye-
loablative regimens were categorized according to
the use of total body irradiation (TBI) and amount of
TBI, either 12 Gy or .12 Gy. All patients in the non-
myeloablative group received 2 Gy of TBI. A lung
shielding protocol for TBI was initiated at the Center
in 1999. To account for potential changes in clinical
practice over time, we considered the year of trans-
plantation as a categorical variable in the analysis.
All PFTs were performed at the Center in accor-
dance with American Thoracic Society guidelines[16-18]. Pulmonary function assessments included
the percentage of predicted forced expiratory volume
in 1 second (FEV1) and percentage of predicted
DLCO, which was adjusted for hemoglobin level. As
part of the usual protocol, PFTs were performed
before HCT and again at day 100 (day 80 6 20 days)
after HCT regardless of the presence or absence of
symptoms. After discharge from the Center (by day
120), patients were encouraged to return to the Center
for follow-up 1 year (365 days6 100 days) after HCT.
Those who could return for follow-up at that time and
elected to do so underwent PFTs in accordance with
protocol. All pulmonary function values were ex-
pressed as percentage of the predicted values calcu-
lated according to published equations [16, 19].
Absolute change in FEV1 or DLCO was calculated
by subtracting the day 100 or 1 year value from the pre-
transplantation value. Serum creatinine and glutamic
pyruvic transaminase (SGPT) concentrations obtained
most recently before the start of the pretransplantation
conditioning regimen were categorized as normal or
abnormal according to the Center’s laboratory stan-
dards (abnormal values: creatinine,. 1.2 mg/dL; total
bilirubin, . 1.3 mg/dL; SGPT, . 49 U/L).
Two outcomes were considered: early respiratory
failure andNRM. Patients were defined as having early
respiratory failure if they required mechanical ventila-
tion for a nonelective reason within 120 days after
HCT. Respiratory failure occurring after 120 days
was not assessed, because patients are routinely dis-
charged from the Center before 120 days posttrans-
plantation. NRM was defined as death occurring
before clinical evidence of disease relapse was mani-
fested.Statistical Analysis
All statistical analyses were performed using Stata
8.0 (StataCorp, College Station, TX). Pearson’s test
was used to compare categorical variables. Unpaired
t-tests and one-way analysis of variance were used to
compare continuous variables. Paired t-tests and Wil-
coxon’s rank-sum test were used to compare changes
in DLCO. PAM score, including survival probability
and 95% confidence intervals (CIs), were calculated
for all patients who underwent allogeneic HCT as
described previously [11]. Cox proportional hazards
regression models were used to conduct a time-
to-event analysis for respiratory failure and NRM.
Disease relapse was considered a competing event for
NRM. The proportional hazards assumption was
tested using Schoenfeld residuals. The rates of early
respiratory failure and mortality according to pre-
transplantation DLCO were estimated using Kaplan-
Meier curves and assessed using the log-rank test.
Two-sided P values\ .05 were considered statistically
significant.
Table 1. Patient Characteristics and Outcomes According to
Autologous versus Allogeneic HCT
Characteristic
Autologous
HCT (n 5 56)
Allogeneic
HCT (n 5 165)
Age, years (mean ± SD) 41.3 ± 15.3 39.3 ± 13.2
Female patients N (%) 22 (39) 58 (35)
Donor type N (%)
Autologous 56 (100) -
Related, matched 83 (50)
Related, mismatched - 23 (14)
Unrelated - 59 (36)
Diagnosis N (%)
Acute leukemia 5 (8) 83 (50)
Chronic leukemia 0 (0) 28 (17)
Hodgkin lymphoma 14 (22) 7 (4)
Non-Hodgkin lymphoma 14 (22) 10 (6)
Multiple myeloma 13 (20) 8 (5)
Myelodysplastic syndrome 0 (0) 20 (12)
Other 10 (18) 9 (5)
Disease status N (%)
Accelerated phase 0 (0) 8 (6)
Blast crisis 0 (0) 9 (6)
Chronic phase 0 (0) 8 (6)
De novo 1 (2) 5 (3)
Relapse 42 (75) 78 (55)
Remission 12 (21) 33 (23)
Unknown 1 (2) 2 (1)
Percent of predicted DLCO
(median (range))
55.5% (34%-60%) 54% (19%-60%)
Percent of predicted DLCO
category N(%)%
50%-60% 49 (87) 118 (71)
40%-50% 6 (11) 34 (21)
< 40% 1 (2) 13 (8)
Respiratory failure N (%) 10 (18) 56 (34)
NRM N (%) 27 (48) 104 (63)
DLCO indicates diffusion capacity of the lung for carbon monoxide;
NRM, nonrelapse mortality. Numbers represent either mean 6 stan-
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Between January 1, 1990, and December 31, 2005,
we identified 56 patients who underwent autologous
HCT and 165 patient who underwent allogeneic
HCT with a pretransplantation DLCO# 60% (Table
1). The median DLCO was 55% (range, 35% to 60%)
in those undergoing autologous HCT and 54%
(range, 18% to 60%) in those undergoing allogeneic
HCT. The majority of patients had a pretransplanta-
tion DLCO between 40% and 60%. Among the 56 pa-
tients undergoing autologous HCT, only 1 (2%) had
a DLCO\40%. Among the 165 patients undergoing
allogeneic HCT, 13 (8%) had a DLCO\ 40%.
To assess whether lower DLCO was associated
with demographic and physiological differences, we
combined the patients undergoing autologous and
allogeneicHCTand then divided this group into 3 sub-
groups according to pretransplantation DLCO: 50%-
60%, 40%-49%, and\ 40%. There were no signifi-
cant differences in age at transplantation, conditioning
regimen, donor type, disease risk, pretransplantation
renal and liver function, and pretransplantation FEV1
among the 3 groups (Table 2). Only 24 (15%) of the
165 patients who underwent allogeneic HCT received
a nonmyeloablative conditioning regimen. Among
these 24 patients, 6 (25%) developed respiratory failure
and 20 (83%) developed NRM. Among the 141
patients who received a myeloablative conditioning
regimen, 50 (35%) developed respiratory failure and
84 (60%) developed NRM.dard deviation, median (range), or count (%).Low Pretransplantation DLCO and Changes
after Transplantation
To assess whether patients with a lower DLCO
pre-HCTwere at risk for low DLCO posttransplanta-
tion, we assessed the change in DLCO by day 100 (n5
99) and 1 year (n5 33) after HCT. Although we found
a borderline trend toward increased DLCO at day 80
posttransplantation in patients with lower pretrans-
plantation DLCO (P 5 .055), we found no significant
differences in the number of patients experiencing a de-
crease in DLCO or an absolute change in DLCO at 1
year posttransplantation (Table 3).Risk of Early Respiratory Failure and NRM
To assess whether patients with lower DLCO pre-
transplantationwere at increased risk for the 2 outcomes
that we considered, we evaluated the time to develop-
ment of early respiratory failure and NRM in separate
models according to pretransplantation DLCO cate-
gory. Regardless of pretransplantationDLCOcategory,
we found no significant difference in the risk for respira-
tory failure or NRM (Table 4). This lack of association
persisted even after adjustment for use of lung shielding
andyearof transplantation.The results remained similarwhen the analysis was stratified according to whether
patients undergoing allogeneic HCT received a non-
myeloablative or amyeloabative conditioning regimen.
To ensure that this lack of association dis not result
from the way in which the DLCO categories were de-
termined, we also dichotomized the DLCO categories
according to 2 additional DLCO thresholds. When
patients with a pretransplantation DLCO of 45%
were compared to patients with a DLCO \ 45%
(n 5 29), the risk for respiratory failure (hazard ratio
[HR] 5 1.36; 95% CI 5 0.69 to 2.67; P 5 .370) and
NRM (HR 5 1.31; 95% CI 5 0.74 to 2.30; P 5
.354) still did not differ significantly. This was also
true when the DLCO threshold was set at 40%.
Patients with a pretransplantation DLCO \ 40%
(n 5 14) did not have a significantly increased risk
for respiratory failure (HR 5 1.41; 95% CI 5 0.57
to 3.5; P 5 .3462) or NRM (HR 5 1.22; 95% CI 5
0.79 to 1.87; P 5 .37). Adjustment for the use of
lung shielding did not significantly affect these risk
estimates.
Given that the results of previous studies have sug-
gested using a more comprehensive approach for risk
Table 2. Baseline Clinical Characteristics and PAM Scores According to DLCO Category
Characteristic
Pretransplantation Percent of Predicted DLCO
50%-60% (n 5 167) 40%-49% (n 5 40) < 40% (n 5 14) P value
Age, years median (range) 41.7 (16.1-70.7) 40.5 (21.4-67.9) 35.3 (15.7-54.15) .677
Conditioning regimen N (%)
Nonmyeloablative 12 (7) 7 (17) 5 (36) .066
Non-TBI 67 (40) 13 (33) 3 (21)
TBI with # 12 Gy 42 (25) 9 (22) 3 (21)
TBI with > 12Gy 46 (28) 11 (28) 3 (21)
Donor type N (%)
Autologous 49 (29) 6 (15) 1 (7) .294
Matched related 58 (35) 18 (45) 7 (50)
Mismatched related 42 (25) 12 (30) 5 (36)
Unrelated 18 (11) 4 (10) 1 (7)
Disease risk N (%)
Low 9 (5) 2 (5) 0 (0) .384
Moderate 47 (28) 6 (15) 5 (36)
High 111 (66) 32 (80) 9 (64)
Serum alanine median (range)
aminotransferase, U/L
26.0 (6-476) 26 (5-217) 31 (2-100) .6
Serum creatinine, (median (range)) mg/dL 0.8 (0.3-5.1) 0.85 (0.4-8.7) 0.95 (0.4-2.4) .750
Percent of predicted FEV1 (median (range)) 74% (39%-111%) 66% (35%-90%) 52% (26%-100%) .06
PAM score* (median (range)) 30.69 (15-42) 31.74 (15-43) 32.0 (26-43) .997
DLCO indicates diffusion capacity of the lung for carbon monoxide; TBI, total body irradiation; Fev1, forced expiratory volume in 1 second; PAM,
Pretransplant Assessment of Mortality; HCT, hematopoietic cell transplantation. Numbers represent either median (range) or count (%).
*PAM score calculated only for patients undergoing allogeneic HCT.
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more comprehensive assessment of mortality risk—
the PAM score—can more effectively risk-stratify
patients compared with the DLCO alone. Because
the PAM score was developed for patients undergoing
allogeneic HCT, the patients undergoing autologous
HCT were excluded from this portion of the analysis.
The average PAM score was similar for all DLCO cat-
egories (Table 2). But when the PAM scores of all 165
patients undergoing allogeneic HCT were considered
together, it became apparent that the PAM score was
somewhat normally distributed, with a median of 30
(mean, 30.5) and a range of 17 to 43 (Figure 1), associ-
ated with survival probabilities ranging from 79%
(95% CI 5 75% to 83%) to 5% (95% CI 5 3% to
8%).
When we subdivided the patients according to
PAM score quartiles, we found that the patients in
the highest PAM score quartile had a 4-fold increaseTable 3. Change in DLCO by Day 100 and 1 Year Posttransplantat
Time Interval
Pretransplantatio
50%-60% 40
Pretransplantation to day 80
Number experiencing 39/75 (52%) 12
Increase in DLCO 5.1% 14
Change in DLCO (240.7% to 96%) (2
Pretransplantation to 1 year
Number experiencing 12/27 (44%) 3/5
Increase in DLCO 210.3% 2.3
Change in DLCO (243.3% to 64.4%) (2
DLCO indicates diffusion capacity of the lung for carbon monoxide. Numbers r
change in DLCO (range) during the designated time intervals.in risk for NRM compared with those in the lowest
PAM score quartile (HR 5 4.38; 95% CI 5 2.69 to
7.14). We also found a significant stepwise increase
in NRM risk and lower survival rates with increasing
PAM score quartile (Table 4). Figure 2 shows survival
curves for NRM according to PAM score quartile. Ad-
justment for the use of lung shielding had no signifi-
cant effect on the risk estimates; however, adjustment
for year of transplantation did influence the risk esti-
mates slightly. The HRs for quartiles 2 to 4 compared
with quartile 1 were as follows: quartile 2, HR 5 1.22
(95% CI 5 0.64 to 2.33; P 5 .542); quartile 3, HR 5
2.04 (95% CI 5 1.14 to 3.65; P 5 .017); quartile 4,
HR 5 6.35 (95% CI 5 3.29 to 12.28; P \ .001).
When we stratified this analysis by myeloablative ver-
sus nonmyeloablative status, we found no significant
association among the patients receiving nonmyeloa-
blative conditioning and no significant change in
effect size among those receiving myeloablativeion According to Pretransplantation DLCO Category
n Percent of Predicted DLCO
%-49% < 40% P value
/17 (71%) 5/7 (71%) .055
.9% 20.5%
32.7% to 55.8%) (211.1% to 415.8%)
(60%) 1/1 (100%) .235
% 22.3%
33.3% to 77.8%)
epresent patients who experienced an increase in DLCO (%) and median
Table 4. Risk of Developing Respiratory Failure and NRM According to Pretransplantation DLCO Category and PAM Score
Number of cases (%) HR (95% CI) P value
Respiratory failure* 66
Percent of predicted DLCO
50%-60% 47/167 (28) Referent -
40%-49% 14/40 (35) 1.37 (0.76-2.49) .298
< 40% 5/14 (36) 1.50 (0.60-3.78) .388
NRM* 131
Percent of predicted DLCO
50%-60% 92/167 (55) Referent -
40%-49% 29/40 (73) 1.28 (0.88-1.87) .198
< 40% 10/14 (71) 1.37 (0.77-2.42) .282
PAM score category†
Quartile 1 (17-27) 28/37 (76) Referent -
Quartile 2 (28-31) 18/34 (53) 1.78 (1.08-2.95) .025
Quartile 3 (32-33) 28/55 (51) 2.27 (1.42-3.65) .001
Quartile 4 (35-42) 30/39 (77) 4.38 (2.69-7.14) < .001
*DLCO indicates diffusion capacity of the lung for carbon monoxide; PAM, Pretransplant Assessment of Mortality; HCT, hematopoietic cell transplan-
tation; NRM, nonrelapse mortality. Analysis includes patients undergoing autologous and allogeneic HCT (n 5 221).
†Analysis restricted to NRM in patients undergoing allogeneic HCT (n 5 165).
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conditioning, the HRs for quartiles 2 to 4 compared
with quartile 1 were as follows: quartile 2, HR 5
1.41(85% CI 5 0.66 to 3.03; P 5 .377); quartile 3,
HR5 1.98 (95%CI5 0.98 to 4.03; P5 .059); quartile
4, HR 5 6.95 (95% CI 5 3.32 to 14.57; P\ .001).
Although the PAM score was not originally
designed for assessing the risk of respiratory failure,
we also examined whether a higher PAM score was
associated with increased respiratory failure risk.
Among the patients undergoing allogeneic HCT,
a PAM score in the highest quartile was associated
with a 2.4-fold increased risk of respiratory failure
(95% CI 5 1.14 to 5.02; P 5 .02). The association
with lower PAM quartiles was not statistically signifi-
cant. This association with the highest PAM score
quartile was increased after we adjusted for year of
transplantation (HR 5 3.68; 95% CI 5 1.58 to 8.54;
P5 .002). When we stratified this analysis by myeloa-
blative versus nonmyeloablative status, the association0
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Figure 1. Histogram for distribution of the PAM scores among patients
undergoing allogeneic HCT. Median score, 30 (mean, 30.5; range, 17
to 43).remained only among the patients who received mye-
loablative conditioning (HR 5 3.52 adjusted for year
of transplantation; 95% CI 5 1.45 to 8.56; P 5 .005).DISCUSSION
DLCO, most commonly assessed by the single-
breath carbon monoxide method [17, 20], is a measure
of a patient’s ability to absorb alveolar gases into the
capillary blood flow, reflecting alveolar membrane
thickness, hematocrit level, cardiac output, and het-
erogeneity in the distribution of the diffusion capacity
to regional ventilation and perfusion (in patients with
pulmonary disease) [21]. DLCO can be decreased as
a result of compromise of any one or a combination
of these variables, leading to a reduction in the alveolar
capillary interface. Unfortunately, DLCO is the most
widely varying parameter measured in PFTs, particu-
larly in the presence of a restrictive or an obstructive0.00
0.20
0.40
0.60
0.80
1.00
0 .5 1 1.5 2 2.5 3 3.5 4 4.5 5
Years after transplant
Nonrelapse mortality
Figure 2. Kaplan-Meier curves for NRM according to PAM score quar-
tile (P\.001). Solid line, 17 to 28; short-dashed line, 29 to 31; dotted
line, 32 to 34; long-dashed line, 35 to 42.
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uals have significant variability in DLCO measure-
ments [27, 28]. Furthermore, selecting reference
equations from the 9 or more equations that are
currently available remains a problem [17], resulting
in wide differences among different reference equa-
tions and different laboratories. For instance, our
Center uses a more conservative Crapo reference
equation, which can significantly underestimate the
DLCO compared with other reference equations.
Thus, despite the initial findings of Crawford and
Fisher [8], using the DLCO in the absence of other co-
morbidities as the sole exclusion criterion for stem cell
transplantation may not be ideal.
Our findings (\60%) of such high respiratory fail-
ure andNRMrates in this subpopulation clearly indicate
thatDLCOis a reasonable screening tool for identifying
high riskpatients, consistentwith similarfindings in a re-
cent analysis of a more contemporaneous cohort [12].
However our findings in the present study reveal 2 haz-
ards of using DLCO to determine eligibility for trans-
plantation when the DLCO is low. First, we found no
evidence of any stepwise relationship between pre-
HCT DLCOs # 60% and the transplantation out-
comes that we evaluated. Although this might reflect
the ineffectiveness of using a DLCO value of 60% as
a threshold, our additional analyses evaluating 40%
and 45% as alternative thresholds demonstrated that
this is an unlikely explanation. Amore likely explanation
is that aDLCOof# 60%is simplynot a sufficiently spe-
cific parameter for risk-stratifying patients. Second, us-
ing a DLCO threshold of 60% to exclude patients
from transplantation in the absence of other comorbid-
itiesmaypossibly reject somepatientswhomightbenefit
from this procedure. This is clearly demonstrated by
our PAM score analysis, which found that a significant
portion of the patients with a DLCO # 60%, not only
had an excellent estimated survival probability, but
ultimately actually survived to the 5-year mark.
The present study is not without limitations, how-
ever. First, despite their low pretransplantation
DLCO values, the patients in the study were neverthe-
less selected for transplantation. It is possible that
clinical assessment at the time of pretransplantation
evaluation revealed these patients to be more physio-
logically fit than was apparent based on their pretrans-
plantation DLCO, thereby supporting a decision to
proceed; however, it also is possible that these patients
had few treatment alternatives, and that transplanta-
tion was selected as a last resort despite severe physio-
logical limitations. Given the normally distributed
PAM scores in the patients undergoing allogeneic
HCT, we believe that a combination of both of these
explanations is most likely. Second, this study included
very few patients with a pretransplantation DLCO in
the lowest range, even when the patients were
evaluated using 2 alternative DLCO thresholds. Thismay have limited our ability to detect an association
between the degree of DLCO compromise and the
outcomes considered. Unfortunately, given the cur-
rent practice of excluding patients with a low DLCO
from transplantation, gathering a group of patients
with extremely low DLCO for such an analysis is
difficult. Finally, it should be recognized that the
lack of association between DLCO and PAM score
with these outcomes in patients receiving nonmyeloa-
blative conditioning is not conclusive, because only 24
patients received a nonmyeloablative conditioning
regimen in the present study. As more data are accu-
mulated for nonmyeloablative conditioning, addi-
tional analyses will be needed.
In summary, our findings suggest that, although
the pretransplantation DLCOmay be useful for initial
identification of patients at greater risk for poorer stem
cell transplantation outcomes, this approach should no
longer be considered as the sole eligibility criterion for
patients with a pretransplantation DLCO below the
eligibility threshold. Although a low DLCO alone
probably does identify patients at risk for poor out-
come, a more comprehensive risk-stratification tool
However that can more accurately estimate the mor-
tality risk of allogeneic HCT even in patients with
the lowest DLCO values should be considered. In-
cluding pretransplantation DLCO as part of such
a comprehensive risk assessment tool will allow clini-
cians to more accurately identify patients who will
benefit from transplantation and more effectively
counsel those at elevated risk for poor transplantation
outcomes.ACKNOWLEDGMENTS
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